Small-Angle X-ray Scattering for Pharmaceutical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Small-Angle X-ray Scattering for Pharmaceutical Applications
The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.


Pharmaceutical Technology
Volume 34, pp. s32-s37

References

1. Fifty Years of X-ray Diffraction, P.P. Ewald, Ed. (A. Oosthoek's Uitgeversmaatschappij, Utrecht, 1962).

2. M. Lambert, Acta Crystallogr. 57 (1), 1–3 (2001).

3. J. Schurz, Colloid Polym. Sci. 273 (10), 994–995 (1995).

4. Small Angle X-ray Scattering, O. Glatter and O. Kratky, Eds. (Academic Press, London, 1982) 4f.

5. H. Schnablegger and Y. Singh, "A Practical Guide to SAXS," (Anton Paar, Graz, Austria, 2006).

6. J. Lake, Acta Crystallogr. 23 (2), 191 (1967).

7. G.R. Strobl, Acta Crystallogr. A 26 (3), 367–375 (1970).

8. M. Soliman, B.J. Jungnickel, and E. Meister, Acta Crystallogr., A, Found. 54 (5), 675–681 (1998).

9. C. Jeffries et al., J. Mol. Biol. 377 (4), 1186–1199 (2008).

10. H. Schnablegger, "Is Smearing An Issue?" (Anton Paar Graz, Austria, 2007).

11. M. Muthukumar, C.K. Ober, and E.L. Thomas, Science 277 (5330), 1225–1232 (1997).

12. G.M. Whitesides, J.P. Mathias, and C.T. Seto, Science 254 (5036), 1312–1319 (1991).

13. G.M. Whitesides and B. Crzybowski, Science 295 (5552), 2418–2421 (2002).

14. A.M. Edwards et al., Nat. Struct. Biol. 7 (11), 970–972 (2000).

15. R.F. Fischetti et al., J. Synchrotron Radiat. 10 (5), 398–404 (2003).

16. M. Hirai et al., J. Synchrotron Radiat. 9 (4), 202–205 (2002).

17. D.M. Tiede, R. Zhang, and S. Seifert, Biochemistry 41, 6605–6614 (2002).

18. R. Zhang, P. Thiyagarajan, and D.M. Tiede, J. Appl. Crystallogr. 33 (3), 565–568 (2000).

19. D.I. Svergun and M.H.J. Koch, Rep. Prog. Phys. 66 (10), 1735–1782 (2003).

20. J. Trewhella and J.K. Krueger, Methods Mol. Biol. 173, 137–159 (2002).

21. P. Chacon et al., Biophys. J. 74 (6), 2760–2775 (1998).

22. P. Chacon et al., J. Mol. Biol. 299 (5), 1289–1302 (2000).

23. D. Svergun, Biophys. J. 76 (6), 2879–2886 (1999), erratum in 77, (5), 2896–2896 (1999).

24. G. Fritz, A. Bergmann, and O. Glatter, J. Chem. Phys. 113 (21), 9733–9740 (2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here